Search clinical trials for: AZD9567 Monohydrat

Total 609 results

AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.

Rheumatoid Arthritis

Germany, United Kingdom
AstraZeneca

Completed

A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis (INCA)

Cystic Fibrosis

Sweden, Russian Federation, United Kingdom, Poland, Denmark, Germany
National Cancer Institute (NCI)

Completed

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
AstraZeneca

Completed

A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.

Rheumatoid Arthritis | Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Tolerability | Safety

Germany
AstraZeneca

Completed

Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment

Renal Impairment

United States
AstraZeneca

Completed

AZD9668 Relative Bioavailability

Chronic Obstructive Pulmonary Disease

Germany
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
AstraZeneca

Completed

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

Cancer | Advanced Solid Malignancies

Japan
AstraZeneca

Completed

AZD9668 Relative Bioavailability

Chronic Obstructive Pulmonary Disease

Germany
AstraZeneca

Completed

Phase I, Exploratory, Single Centre, Single Oral Dose AZD9668 and Intravenous Microdose of [C14] AZD9668, Healthy Subject

Healthy

United Kingdom
AstraZeneca

Completed

AZD9056 Relative Bioavailability Study

Healthy

United Kingdom
AstraZeneca

Terminated

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

Cancer | Advanced Solid Malignancies

United States, Italy, United Kingdom, France, Germany, Spain, Netherlands
AstraZeneca
Parexel

Completed

A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male Subjects

Healthy Volunteers

United Kingdom
AstraZeneca
Quotient Sciences

Completed

Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects

Cardiovascular Disease

United Kingdom
AstraZeneca

Completed

A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany
Oxford University Hospitals NHS Trust
University of Oxford; Cancer Research UK; National Institute for Health Research...

Completed

Phase 1 Trial of CXD101 in Patients With Advanced Cancer

Advanced Cancer

United Kingdom
AstraZeneca

Completed

A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis (NEPAL)

Bronchiectasis

United Kingdom, Canada
AstraZeneca

Completed

Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Romania, Ukraine, Denmark, Netherlands, Canada
AstraZeneca

Completed

A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Poland, Germany, Philippines, Ukraine, Japan, United States, Australia, Canada, Slovakia, Taiwan, Russian Federation
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Urothelial Carcinoma

China
AstraZeneca

Terminated

A Single and Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Japanese Subjects (JSMAD)

Healthy

United Kingdom
AstraZeneca

Completed

A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects

Heart Failure

United Kingdom
AstraZeneca

Completed

AZD8566 Food Effect/Microtracer Study

Healthy Volunteer Study

United Kingdom
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males

Healthy Subjects | Pharmacokinetics | Tolerability | Safety

United Kingdom
Abbisko Therapeutics Co, Ltd

Completed

ABSK091 Food Effect Study in Healthy Subjects

Health, Subjective | Food-drug Interaction

Taiwan
AstraZeneca

Terminated

A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease

Healthy | COPD

Sweden
AstraZeneca
Parexel

Completed

Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects

Healthy Volunteers

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose Administration

Heart Failure

United Kingdom
AstraZeneca

Recruiting

A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese (CONTEMPO)

Non-alcoholic Steatohepatitis (NASH)

Austria, Germany, Sweden
AstraZeneca
Parexel

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

Non-alcoholic Steatohepatitis

United Kingdom
AstraZeneca

Completed

Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers (ADME)

Healthy

United Kingdom
AstraZeneca

Completed

Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056

Rheumatoid Arthritis

United Kingdom
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of AZD8566.

Pharmacokinetics

United Kingdom
Denovo Biopharma LLC

Completed

A Study of LY2140023 in Healthy Males and Females

Healthy Volunteers

United Kingdom
AstraZeneca

Withdrawn

A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin

Pharmacokinetics | Pharmacodynamics

Sweden
AstraZeneca

Completed

AZD9164 Single Ascending Dose Study in Healthy Male Subjects

Healthy

Sweden
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of AZD8566.

Healthy Volunteer

United Kingdom
AstraZeneca

Recruiting

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
Cambridge University Hospitals NHS Foundation Trust
GlaxoSmithKline; University of Cambridge; Royal Brompton & Harefield NHS Foundation... and other collaborators

Completed

Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen. (EVOLUTION)

Chronic Obstructive Pulmonary Disease

United Kingdom
AstraZeneca

Completed

Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol

Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, Czech Republic, Poland, Hungary, Romania, Slovakia
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene Amplification

United States, Canada
Estetra

Recruiting

Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women

Sexual Dysfunction, Physiological

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

The Tolerance, Pharmacokinetics of Jaktinib in Healthy Volunteers

Healthy Volunteers

China
Mirum Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VISTAS)

Primary Sclerosing Cholangitis

United States, United Kingdom, Israel, Germany, Canada
Biologische Heilmittel Heel GmbH

Completed

Explorative Efficacy Profile of Neurexan® in an Experimental Acute Stress Setting in Healthy Subjects (NEUPRO-DB)

Acute Stress Reaction

Germany
Prescient Therapeutics, Ltd.
VioQuest Pharmaceuticals

Completed

Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer

Cancer

United States
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed Conditions

To Determine Bioequivalence Under Fed Conditions

Canada
Teva Pharmaceuticals USA

Completed

Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions

Healthy

United States
Leadiant Biosciences, Inc.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Active, not recruiting

Multi-Center Study of ManNAc for GNE Myopathy (MAGiNE)

GNE Myopathy

United States
Prescient Therapeutics, Ltd.
VioQuest Pharmaceuticals

Completed

Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies

Leukemia | Hematologic Malignancies

United States

3

Subscribe